Treatment of Elderly Patients With Mantle Cell Lymphoma

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 208-213

  Kluin Nelemans, Hanneke C ^a   Doorduijn, Jeanette K ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MITOXANTRONE; OXALIPLATIN; PLACEBO; PREDNISONE; PROCARBAZINE; PURINE DERIVATIVE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR SOX11; VINCRISTINE; YTTRIUM 90;

AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; HUMANS; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960495592     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.008     Document Type: Article

References (45)

1. 't Veer M.B., De Jong D., MacKenzie M., et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009, 144:524-530.
2. Gressin R., Caulet-Maugendre S., Deconinck E., et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematology 2010, 95:1350-1357.
3. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
4. Geisler C.H. Front-line treatment of mantle cell lymphoma. Haematology 2010, 95:1241-1243.
5. Pott C., Hoster E., Delfau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2009, 115:3215-3223.
6. Dreyling M., Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009, 542-551.
7. Ghielmini M., Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476.
8. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
9. Schulz H., Bohlius J., Skoetz N., et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007, CD003805.
10. Hiddemann W., Dreyling M. Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr Treat Options Oncol 2003, 4:219-226.
11. Zinzani P.L., Magagnoli M., Moretti L., et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000, 18:773-779.
12. Zinzani P.L., Magagnoli M., Moretti L., et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica 1999, 84:1002-1006.
13. Foran J.M., Rohatiner A.Z., Coiffier B., et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999, 17:546-553.
14. Rummel M.J., Al Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
15. Rummel M.J., Kaiser U., Balser C., et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphoma-final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. ASH Annual Meeting Abstracts. Blood 2010, 116:373.
16. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
17. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab is superior in respect of pregression free survival and CR ratre when compared to CHOP plus rituximab in first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphoma: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. ASH Annual Meeting Abstracts. Blood 2010, 114:168-169.
18. Herold M., Schulze A., Niederwieser D., et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006, 132:105-112.
19. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
20. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
21. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
22. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
23. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
24. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
25. Gressin R., Houot R., Uribe M.O., et al. Final results of the RiPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A phase II prospective study of the GOELAMS Group [abstract]. Blood 2010, 116:1151.
26. Bauwens D., Maerevoet M., Michaux L., et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005, 131:338-340.
27. Ghielmini M., Hsu Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
28. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998, 339:21-26.
29. Leitch H.A., Gascoyne R.D., Chhanabhai M., Voss N.J., Klasa R., Connors J.M. Limited-stage mantle-cell lymphoma. Ann Oncol 2003, 14:1555-1561.
30. Hiddemann W., Unterhalt M., Herrmann R., et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998, 16:1922-1930.
31. Teodorovic I., Pittaluga S., Kluin-Nelemans J.C., et al. Efficacy of four different regimens in 64 mantle cell lymphoma cases-clinicopathological comparison with 498 other non-Hodgkin's lymphoma sybtypes-EORTC Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819-2826.
32. Boer de C.J., Kluin-Nelemans J.C., Dreef E.J., Kluin Ph.M., Schuuring E., van Krieken J.H.J.M. Involvement of the CCND1 gene in hairy cell leukemia. Ann Oncol 1996, 7:251-256.
33. Martin P., Chadburn A., Christos P., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
34. Fernandez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
35. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
36. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
37. Weigert O., Weidmann E., Mueck R., et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multicenter observation study. Leuk Lymphoma 2009, 50:716-720.
38. Bethge W.A., Lange T., Meisner C., et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase II study. Blood 2010, 116:1795-1802.
39. Rodriguez J., Gutierrez A., Palacios A., et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007, 48:2172-2178.
40. Weide R., Hess G., Koppler H., et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007, 48:1299-1306.
41. Ruan J., Martin P., Coleman M., et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010, 116:2655-2664.
42. Morschhauser F., Depil S., Jourdan E., et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007, 18:370-375.
43. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
44. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
45. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008, 19:247-253.